Xinhui People's Hospital

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

Retrieved on: 
Wednesday, November 17, 2021
People, Antibody-dependent enhancement, Safety, NIAID, Achievement, Foundation for the National Institutes of Health, Tsinghua University, AIDS Clinical Trials Group, Plasma, National Institute of Allergy and Infectious Diseases, Xinhui People's Hospital, Clinical trial, Infection, R, Hospital, HIV, B.1.1.7, National Medical Products Administration, Food, Senior, ACTG, Severe acute respiratory syndrome coronavirus 2, CDE, COVID-19, Epsilon, MDR, Regulation of tobacco by the U.S. Food and Drug Administration, National Institute, Hepatitis B, CNS, Center for Drug Evaluation and Research, Award, Company, Beta, Therapy, EUA, Death, AIDS, Central nervous system, XDR, Patient, NIH, Risk, FDA, NMPA, Pharmaceutical industry

The recognition is for the R&D achievements of Brii Bio's investigational monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"), for the treatment of COVID-19.

Key Points: 
  • The recognition is for the R&D achievements of Brii Bio's investigational monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"), for the treatment of COVID-19.
  • In parallel, the company has submitted the Phase 3 interim data to China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA).
  • The BioCentury-Bayhelix China Healthcare Awards celebrate outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem.
  • R&D Achievement of the Year recognizes one company for a scientific discovery in China with direct impact to drug R&D or a significant achievement in pharmaceutical development milestones.

Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect

Retrieved on: 
Wednesday, November 3, 2021
People, Coronavirus, Research, Artemisinin, National Medical Products Administration, Guangzhou University, Guangzhou Medical University, Disease, Association, Tablet, Firestone Institute for Respiratory Health, Guangzhou University of Chinese Medicine, Infection, Joint Medical Service (Germany), TCM, Efficacy, National Health Commission, Genetics, Malaria, Hospital, Social media, International Journal of Antimicrobial Agents, COVID-19, Safety, Antimicrobial, Xinhui People's Hospital, Observation, Artemisia annua, Treatment, Canadian International Council, Pharmaceutical industry

These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".

Key Points: 
  • These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".
  • This implies how the scientific community and the general public are in desperate need of effective drug treatments for COVID-19.
  • And they have been the drug of first choice recommended by the National Health Commission of China since 2009.
  • Going ahead, the drug is expected to have a greater role to play in the treatment of other diseases," said Zhu Layi, president of Guangdong New South Group.